Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Research on Clinical Recovery and Maintenance Strategies for CHB

Research on Clinical Recovery and Maintenance Strategies for Chronic Hepatitis B

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Collect basic information of patients before antiviral treatment and when HBsAg disappears, and divide them into three groups A, B, and C based on baseline anti HBs titers after informed consent. During the follow-up period of all patients, clinical biochemistry, virology (HBVDNA, HBVRNA), serological indicators (HBsAg, anti HBs, HBeAg, anti HBe, HBcrAg, anti HBc), AFP, Fibroscan, liver imaging examinations will be conducted every 3-6 months, and blood samples will be retained for monitoring the frequency of immune cells (pDC, Treg) and the expression of functional molecules, as well as cytokines (IFN - γ, IP-10, IL-10, and TGF - β). Observe the sustained response rate and recurrence rate of virological and serological indicators, as well as the incidence of hepatitis and liver cancer during the follow-up period.

Who May Be Eligible (Plain English)

Who May Qualify: - Age between 18 and 65 years old; - Gender is not limited; - CHB patients who meet the diagnostic criteria of the 2019 edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B \[5\]; - Confirmed interferon treatment resulted in HBsAg disappearance, HBeAg negativity, and HBV DNA below the lower detection limit and cessation Patients treated with interferon; - Sign a written willing to sign a consent form form. Who Should NOT Join This Trial: - Merge with other hepatitis virus (HCV, HDV) infections; - Autoimmune liver disease; - HIV infection; - Long term alcohol abuse and/or other liver damaging drugs; - Mental illness; - Evidence of liver tumors (liver cancer or AFP\>100ng/ml); - Decompensated cirrhosis; - Individuals with serious diseases of the heart, brain, lungs, kidneys, and other systems who cannot participate in long-term follow-up. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age between 18 and 65 years old; * Gender is not limited; * CHB patients who meet the diagnostic criteria of the 2019 edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B \[5\]; * Confirmed interferon treatment resulted in HBsAg disappearance, HBeAg negativity, and HBV DNA below the lower detection limit and cessation Patients treated with interferon; * Sign a written informed consent form. Exclusion Criteria: * Merge with other hepatitis virus (HCV, HDV) infections; * Autoimmune liver disease; * HIV infection; * Long term alcohol abuse and/or other liver damaging drugs; * Mental illness; * Evidence of liver tumors (liver cancer or AFP\>100ng/ml); * Decompensated cirrhosis; * Individuals with serious diseases of the heart, brain, lungs, kidneys, and other systems who cannot participate in long-term follow-up.

Treatments Being Tested

BIOLOGICAL

baseline anti-HBs titer

Patients with baseline anti-HBs titer\<100 mIU/ml were randomly divided into two groups, group B and group C. Group B did not intervene, while group C received hepatitis B vaccine intervention and observed its indicators.

Locations (1)

Beijing Ditan Hospital
Beijing, Beijing Municipality, China